Siegel, Patrick M.
Bojti, István
Bassler, Nicole
Holien, Jessica
Flierl, Ulrike
Wang, Xiaowei
Waggershauser, Philipp
Tonnar, Xavier
Vedecnik, Christopher
Lamprecht, Constanze
Stankova, Ivana
Li, Tian
Helbing, Thomas
Wolf, Dennis
Anto-Michel, Nathaly
Mitre, Lucia Sol
Ehrlich, Julia
Orlean, Lukas
Bender, Ileana
Przewosnik, Anne
Mauler, Maximilian
Hollederer, Laura
Moser, Martin
Bode, Christoph
Parker, Michael W.
Peter, Karlheinz
Diehl, Philipp
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft
Deutsche Gesellschaft für Kardiologie-Herz und Kreislaufforschung.
National Health and Medical Research Council (1174098)
Deutsche Stiftung für Herzforschung
Leukemia Foundation
European Research Council (853425)
Article History
Received: 31 July 2020
Accepted: 18 January 2021
First Online: 15 March 2021
Compliance with ethical standards
:
: The authors declare that they have no conflict of interest.
: Experiments involving human or animal samples were approved by the institutional review board of the University of Freiburg, Germany, and the Alfred Hospital, Melbourne, Australia. Participants or their legal representatives (in the case of ECMO patients) gave written informed consent in accordance with the Declaration of Helsinki. Both observational studies were registered in the German Clinical Trials Register: DRKS00005277 (STEMI-patients), DRKS00011106 (ECMO patients).
: All patients or their legal representatives provided informed consent prior to inclusion into the study.
: This manuscript does not include any pictures of patients and is not a case report. The presentation of data in this manuscript do not allow the identification of study participants. All patients or their legal representatives provided informed consent prior to inclusion into the study.